UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CLINICAL RESEARCH

IQVIA

I

IQVIA

Clinical ResearchDurham, United States
Visit Website

About IQVIA

The world's largest contract research organisation by revenue, IQVIA was formed in 2016 through the merger of IMS Health and Quintiles, bringing together the industry's leading data and analytics business with one of its most established clinical research organisations. The result is a company that sits at an unusual intersection: it provides the intelligence that shapes drug development decisions and the operational infrastructure to run the trials themselves.

Data, Technology & Real-World Evidence

At the core of IQVIA's offering is its IQVIA CORE platform, which aggregates longitudinal patient-level data from more than 100 countries. Pharmaceutical manufacturers, regulators and payers rely on this asset for market analytics, real-world evidence generation, and commercial planning. The company's technology division delivers AI-powered trial design tools, site selection models, and decentralised clinical trial infrastructure under its Virtual Trials suite, accelerating study timelines by reducing patient recruitment friction.

Clinical Research Operations

IQVIA's clinical research services span all phases of development, from first-in-human studies through post-marketing surveillance, across oncology, central nervous system disorders, cardiovascular disease, immunology, rare diseases, and infectious disease. The company operates in more than 100 countries and employs tens of thousands of staff globally, making it one of the few CROs with the geographic reach to run truly global pivotal trials from a single contract.

Listed on the New York Stock Exchange under the ticker IQV, IQVIA is headquartered in Durham, North Carolina, and reports revenue in the billions annually, placing it among the largest life science services companies in the world. Its commercial services division also supports pharma clients with sales force deployment, medical affairs outsourcing, and regulatory consulting, giving it end-to-end coverage across the drug development and commercialisation lifecycle.

Further information is available at iqvia.com.

Similar Companies

More in Clinical Research

A

AXIS

Founded in 2004 and headquartered in Hyderabad, Telangana, Axis Clinicals Limited has grown into an internationally recognised contract research organisation operating across India, the United States, and Mexico. With a workforce of more than 500 professionals, the company serves pharmaceutical, biotechnology, and generic drug sponsors seeking a single partner for early- and late-phase development. The company's core strength lies in bioavailability and bioequivalence (BA/BE) studies, which account for approximately half of annual revenue and are conducted from dedicated facilities in Hyderabad and Ahmedabad. Alongside BA/BE work, Axis Clinicals delivers pharmacokinetic and pharmacodynamic (PK/PD) patient studies, Phase I through Phase IV clinical trials, bio-analytical laboratory services, and a clinical central laboratory. Supporting disciplines include project management, PK biostatistics and programming, medical writing, regulatory affairs, clinical data management, and quality assurance and compliance. Facilities carry DCGI and NABL accreditation under ISO 15189 and have been inspected and approved by the US FDA, UK MHRA, Brazil ANVISA, and France ANSM, confirming adherence to ICH GCP and GLP guidelines across international markets. A parallel US entity, Axis Clinicals USA, serves North American sponsors seeking early-phase trial unit capabilities. Further information is available at axisclinicals.com.

View profile
A

ARC Regulatory

Diagnostic compliance sits at the core of what ARC Regulatory does. Operating as a specialist CRO and regulatory consultancy, the company supports pharmaceutical, diagnostics and laboratory clients navigating the intersection of IVD development, companion diagnostics and clinical research. Headquartered in the United Kingdom, ARC Regulatory positions itself explicitly as a partner for Dx compliance in translational research. The company's service model spans four interconnected pillars. Its regulatory team guides clients through the global regulatory landscape for IVD and CDx development, covering strategy, submissions and ongoing compliance. Clinical services provide IVD and CDx-focused monitoring with a global reach, supporting clinical performance studies from initiation through study close-out. A quality practice delivers QMS auditing, risk management and QMS implementation, while ARC Research Laboratories offers IVD development and validation services using advanced technologies. CRO and Sponsor Delegation for IVD Studies As a full-service CRO, ARC Regulatory guides sponsors through every phase of IVD and CDx clinical development. The company also offers IVD Clinical Study Sponsor Delegation, enabling clients to outsource the initiation and management of IVD studies to ARC's team. This model is particularly relevant to pharma sponsors supporting translational biomarkers in early clinical development, where the company provides proprietary risk-based monitoring of central testing laboratories across the full development life cycle. For diagnostics companies, ARC Regulatory supplies R&D compliance support and full-service CRO capabilities for clinical performance studies, meeting pharmaceutical sponsor expectations. Laboratory clients benefit from analytical testing capabilities, rounding out a broad but IVD-specific service offering. Further information is available at arc-regulatory.co.uk.

View profile
F

Flatiron Health

Founded in 2012 and acquired by Roche in 2018, Flatiron Health has become the leading oncology-specific technology and real-world evidence company in the United States, connecting cancer care and research through a purpose-built data infrastructure. Its work centres on the premise that the information generated during routine cancer treatment holds untapped research value when structured and analysed correctly. The company operates the OncoEMR electronic health record platform, used by community oncology practices across the country, alongside the broader oncology network that aggregates de-identified real-world data from millions of cancer patients. This dataset supports regulatory submissions, label expansions, health technology assessments, and clinical trial optimisation for pharmaceutical and biotechnology companies worldwide. Flatiron's research services division works directly with life sciences sponsors and regulators, including the US Food and Drug Administration, to explore how real-world evidence can supplement or accelerate traditional clinical development pathways. The company is headquartered in New York City and operates as a subsidiary of the Roche Group, giving it access to global oncology expertise while maintaining a focused mandate on cancer data science. Its therapy coverage spans solid tumours and haematological malignancies, with data assets covering breast cancer, lung cancer, colorectal cancer, leukaemia, lymphoma, and many additional indications. Researchers and commercial teams use Flatiron's curated datasets to understand treatment patterns, patient outcomes, and population-level trends in ways that prospective trials alone cannot capture. Further information is available at flatiron.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy